Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free BGMS Stock Alerts

Cyclacel Pharmaceuticals (BGMS) Competitors

Cyclacel Pharmaceuticals logo
$0.88 +0.01 (+0.98%)
Closing price 03:58 PM Eastern
Extended Trading
$0.88 +0.00 (+0.11%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BGMS vs. TLIH, SOS, JBDI, CLWT, and INEO

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? Cyclacel Pharmaceuticals's main competitors and comparable companies include Ten-League International (TLIH), SOS (SOS), JBDI (JBDI), Euro Tech (CLWT), and INNEOVA (INEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Cyclacel Pharmaceuticals compare to Ten-League International?

Ten-League International (NASDAQ:TLIH) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Ten-League International had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 1 mentions for Ten-League International and 0 mentions for Cyclacel Pharmaceuticals. Ten-League International's average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ten-League International Neutral
Cyclacel Pharmaceuticals Neutral

Ten-League International has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ten-League International$59.24M0.29$4.34MN/AN/A
Cyclacel Pharmaceuticals$750K6.47-$3M-$3.64N/A

Ten-League International has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. Ten-League International's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ten-League InternationalN/A N/A N/A
Cyclacel Pharmaceuticals -118.27%-31.60%-27.72%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ten-League International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ten-League International beats Cyclacel Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to SOS?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and SOS (NYSE:SOS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than SOS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$750K6.47-$3M-$3.64N/A
SOS$154.29M0.10-$97.32MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SOS
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled SOS'saverage media sentiment score.

Company Overall Sentiment
Cyclacel Pharmaceuticals Neutral
SOS Neutral

Cyclacel Pharmaceuticals has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market. Comparatively, SOS has a beta of 2.62, meaning that its stock price is 162% more volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 1.9% of SOS shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of SOS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SOS has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. SOS's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-118.27% -31.60% -27.72%
SOS N/A N/A N/A

Summary

SOS beats Cyclacel Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to JBDI?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and JBDI (NASDAQ:JBDI) are both small-cap industrials companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
JBDI
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

JBDI has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. JBDI's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-118.27% -31.60% -27.72%
JBDI N/A N/A N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

JBDI has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$750K6.47-$3M-$3.64N/A
JBDI$8.44M1.47-$2.72MN/AN/A

In the previous week, Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled JBDI'saverage media sentiment score.

Company Overall Sentiment
Cyclacel Pharmaceuticals Neutral
JBDI Neutral

Cyclacel Pharmaceuticals has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market. Comparatively, JBDI has a beta of -1.12, meaning that its stock price is 212% less volatile than the broader market.

Summary

JBDI beats Cyclacel Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Euro Tech?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of Euro Tech shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 79.0% of Euro Tech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Euro Tech has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. Euro Tech's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-118.27% -31.60% -27.72%
Euro Tech N/A N/A N/A

Euro Tech has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$750K6.47-$3M-$3.64N/A
Euro Tech$13.27M0.92$160KN/AN/A

Cyclacel Pharmaceuticals has a beta of -0.38, suggesting that its stock price is 138% less volatile than the broader market. Comparatively, Euro Tech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled Euro Tech'saverage media sentiment score.

Company Overall Sentiment
Cyclacel Pharmaceuticals Neutral
Euro Tech Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Euro Tech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Euro Tech beats Cyclacel Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to INNEOVA?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and INNEOVA (NASDAQ:INEO) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

In the previous week, INNEOVA had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 1 mentions for INNEOVA and 0 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled INNEOVA'saverage media sentiment score.

Company Overall Sentiment
Cyclacel Pharmaceuticals Neutral
INNEOVA Neutral

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cyclacel Pharmaceuticals has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market. Comparatively, INNEOVA has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INNEOVA
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

INNEOVA has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$750K6.47-$3M-$3.64N/A
INNEOVA$58.42M0.17-$400KN/AN/A

INNEOVA has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. INNEOVA's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-118.27% -31.60% -27.72%
INNEOVA N/A N/A N/A

Summary

INNEOVA beats Cyclacel Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGMS vs. The Competition

Export
MetricCyclacel PharmaceuticalsTrading Companies & Distributors IndustryIndustrials SectorNASDAQ Exchange
Market Cap$4.85M$9.50B$10.63B$12.78B
Dividend YieldN/A3.38%97.13%10.78%
P/E Ratio-0.2427.9026.4524.19
Price / Sales6.4723.27355.13128.72
Price / CashN/A47.7324.3136.89
Price / Book0.633.794.856.51
Net Income-$3M$375.39M$611.55M$347.63M
7 Day Performance-3.65%-1.75%-0.92%1.60%
1 Month Performance-3.93%1.19%2.21%5.26%
1 Year PerformanceN/A5.72%11.27%17.85%

Cyclacel Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGMS
Cyclacel Pharmaceuticals
0.8598 of 5 stars		$0.88
+1.0%		N/AN/A$4.85M$750KN/A14
TLIH
Ten-League International
0.1315 of 5 stars		$5.79
-0.2%		N/A-3.5%$17.05M$59.24MN/A64
SOS
SOS
0.3971 of 5 stars		$0.99
+2.6%		N/A-46.6%$15.60M$154.29MN/A170
JBDI
JBDI
0.2071 of 5 stars		$1.35
+3.1%		N/A-36.7%$12.46M$8.44MN/A121
CLWT
Euro Tech
0.6725 of 5 stars		$1.60
+1.9%		N/A+31.2%$11.69M$13.27MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BGMS) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel